ARN-509 is an androgen receptor signaling inhibitor currently in phase 2 clinical trial for castration-resistant prostate cancer (CRPC). How does ARN-509 work to block prostate cancer cells is described below.
Tuesday, September 24, 2013
Friday, September 6, 2013
ABRAXANE® (generic name: nab-paclitaxel) was approved by the FDA as first-line therapy for the metastatic adenocarcinoma of the pancreas when used in combination with gemcitabine. The approval of ABRAXANE is a major development in pancreatic cancer care and is expected to replace gemcitabine alone as a new standard of care for pancreatic cancer.